CClinicalTrials.gg
CompletedNCT02859181Updated Mar 29, 2019

Protein Requirements for Active Adolescent Males (IAAO-AM)

An interventional study of Amino Acid Intake in Healthy, sponsored by University of Toronto. Completed at 1 site in Canada. Open to male participants aged 10 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by University of Toronto · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
10 Years to 15 Years
Sex
Male
01

Study summary

Protein requirements in active individuals have been suggested to be greater than the current recommended dietary allowance (RDA).

Nutritional requirements for dietary amino acids in adolescents have traditionally been determined utilizing the nitrogen balance technique, which is prone to underestimating protein requirements. As a result, there is a need to re-evaluate recommendations in order to characterize how dietary amino acid needs may be modulated by physical activity.

Recent studies using the minimally invasive indicator amino acid oxidation (IAAO) technique have suggested that protein requirements in young men are at least 50% higher than the RDA based on nitrogen balance data.

The purpose of this study is to measure the protein requirement in adolescent, males using the IAAO technique in the presence of a variable intensity exercise stimulus.

02

Conditions studied

  • Healthy

Keywords

  • Increased Metabolic Requirement
03

In context

Lead sponsor

University of Toronto is the lead sponsor of 397 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 15 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy, active adolescent who regularly participates in moderate to vigorous physical activity 5 times a week for a minimum of 1 hour.
  • Being -0.5 to +1.0 years from peak height velocity, determined by the ratio of standing to sitting height, with the maximal age for adolescents being 16 years.
  • Obtaining a minimum level of 8.3 on the Beep Test

Exclusion criteria

Exclusion Criteria (All Subjects):

  • Inability to meet health and physical activity guidelines according to the Physical activity readiness questionnaire (PAR-Q+) and Physical Activity Questionnaire,
  • an inability to adhere to any of the protocol guidelines (i.e. caffeine consumption)
  • a biological age falling outside of the aforementioned ranges
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Active, Adolescent males

    Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d

    Dietary Supplement: Amino Acid Intake

Interventions

  • Dietary supplementAmino Acid Intake

    Amino acid intakes will be varied at 0.2-2.67 g/kg/d

06

What researchers measure

Primary outcomes

  1. 13CO2 ([13]Carbon Dioxide) Excretion (µmol/kg/h)

    Each trial day will assess a different protein intake with 13CO2 excretion defining the level of protein adequacy. Each trial day will be separated by \~1wk washout with all trial being completed in approximately 3 months.

    Time frame: 4 hours per study day

Secondary outcomes

  1. [13C]Phenylalanine Oxidation (µmol/kg/h)

    Each trial day will assess a different protein intake with 13CO2 excretion defining the level phenylalanine oxidation being used as a secondary marker of protein adequacy. Each trial day will be separated by \~1wk washout with all trial being completed in approximately 3 months.

    Time frame: 4 hours per study day

07

Study locations

1 site
  • Goldring Centre for High Performance Sport
    Toronto, Ontario M5S2C9, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02859181
Lead sponsor
University of Toronto
Collaborators
Ajinomoto Co., Inc.
Responsible party
Daniel Moore (Assistant Professor, University of Toronto) — Principal investigator
First posted
Aug 8, 2016
Start date
Oct 2016
Primary completion
Nov 15, 2017
Completion
Apr 30, 2018
Last update
Mar 29, 2019

Study contacts

Daniel Moore, PhD
principal investigator · University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion